Libvatrep is a Small Molecule owned by Novartis, and is involved in 5 clinical trials, of which 4 were completed, and 1 is ongoing.
Libvatrep (SAF-312) inhibits the capsaicin receptor TrpV1, which is expressed on the surface of the eye. The TRPV1 antagonists block the activity of TRPV1, results in the reduction in pain and other integration of diverse painful stimuli. Transient receptor potential vanilloid 1 (TRPV1/VR1) is a non-selective cation channel with high calcium permeability expressed on the peripheral and central terminals of small-diameter sensory neurones. It functions as a polymodal nociceptor at the peripheral nerve terminals and modulates synaptic transmission at the first sensory synapse between dorsal root ganglion (DRG) and dorsal horn neurones.
The revenue for Libvatrep is expected to reach a total of $327m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Libvatrep NPV Report.
Libvatrep is originated and owned by Novartis.
Libvatrep (SAF-312) is under development for the treatment of postoperative or chronic ocular surface ocular pain. The drug candidate is administered through oral route and opthalmic route. It is a new molecular entity (NME).
It was also under development for the treatment of postoperative dental pain and neurogenic detrusor overactivity due to spinal cord lesions.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.
Quick View – Libvatrep
|Highest Development Stage|